積極佈局大健康產業 藥明康德(02359.HK)擬認購1706萬股藥明奧測新發行股份
格隆匯10月18日丨藥明康德(02359.HK)公佈,2019年10月18日,本公司全資子企業WuXi PharmaTech Healthcare FundI L.P.(以下簡稱“藥明基金一期”)、YF Digital Pathology Limited.(以下簡稱“雲鋒基金”)、LBC Sunshine Healthcare Fund L.P.(以下簡稱“清池資本”)及 MayoCollaborative Services, LLC (以下簡稱“Mayo Collaborative Services”)與藥明奧測簽署《認購協議》,藥明一期基金擬認購藥明奧測新發行的1706萬股股份。
藥明奧測依據開曼羣島法律由本公司實際控制人共同控制的企業WuXi LifeScience與Mayo Collaborative Services共同於2018年2月9日設立。基於 MayoClinic全球領先的整合診療理念與經驗,藥明奧測建立了融合多平台、多組學技術能力與臨牀診斷大數據的整合診斷服務平台,致力於為中國醫院和醫生提供一站式診斷決策解決方案(疾病診斷賦能包),實現多病種、全病程的精準診斷。藥明奧測的體外診斷產業賦能平台,助力診療創新者加速完成從研發到商業化的技術轉化,創造共贏共享的產業新生態。
藥明奧測設立時WuXi Life Science持股比例為82%,Mayo CollaborativeServices持股比例為18%。2018年12月11日,WuXi Life Science與 MayoCollaborative Services 同比例認購藥明奧測新發行普通股。
公司稱,精準診斷是精準治療的基礎。隨着國家基於疾病種類相關分組的醫保支付改革的推進,藥明奧測以疾病診斷賦能包為代表的精準診斷領域產品和服務將能夠助力醫生精準診斷,讓醫生把病人治得更好,讓病人得到更好的治療。本次交易是本公司在大健康領域的重要投資舉措,通過投資藥明奧測,賦能精準診斷,可以進一步完善本公司在大健康產業領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.